Skip to main content
SpringerLink
Log in

The Medicinal Chemistry of Glucocorticoid Receptor Modulators

  • Book
  • © 2023

Overview

Authors:
  1. Adrian Hobson

    1. AbbVie Bioresearch Center, Drug Discovery Science and Technology, Worcester, USA

    View author publications

    You can also search for this author in PubMed   Google Scholar

  • Outlines the development of glucocorticoid receptor modulators from 1950 to 2022
  • Shows how prodrugs and metabolic inactivation are applied to drug discovery
  • Presents Antibody-Drug Conjugates for immunology

Part of the book series: SpringerBriefs in Molecular Science (BRIEFSMOLECULAR)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 16.99 USD 39.99
Discount applied Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 16.99 USD 49.99
Discount applied Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (8 chapters)

  1. Front Matter

    Pages i-ix
    Download chapter PDF

  2. Introduction

    • Adrian Hobson
    Pages 1-3

  3. Cortisol Based Glucocorticoids

    • Adrian Hobson
    Pages 5-23

  4. Metabolically Inactivated Glucocorticoids

    • Adrian Hobson
    Pages 25-36

  5. Prodrugs

    • Adrian Hobson
    Pages 37-58

  6. Selective Glucocorticoid Receptor Modulators

    • Adrian Hobson
    Pages 59-97

  7. Computational Approaches

    • Adrian Hobson
    Pages 99-110

  8. Polymers, Particles and Conjugates

    • Adrian Hobson
    Pages 111-124

  9. Conclusion

    • Adrian Hobson
    Pages 125-126

  10. Back Matter

    Pages 127-142
    Download chapter PDF
Back to top

Keywords

About this book

This book covers the design and development of glucocorticoid receptor modulators (GRM) from cortisol to antibody-drug conjugate payloads over the last 70 years. The author starts with an introduction to the background of glucocorticoid receptor modulators as potential therapeutic modalities. This is followed by seven chapters in which he collates and discusses the medicinal chemistry journey of GRMs, reviewing topics such as cortisol-based glucocorticoids, the different approaches that have been pursued to enable chronic dosing of GRM compounds by inactivation in plasma and the liver, the application of prodrugs to GRMs, selective GRMs, targeted delivery of GRMs using polymers and nanoparticles, and rational drug design approaches applied in the development of GRMs. Particular attention is given to the development of glucocorticoid receptor modulators as immunology antibody-drug conjugate payloads. In the book’s final chapter, the author critiques the medicinal chemistry progress madesince the discovery of cortisone and the promise of the latest antibody-drug conjugates that release a GRM payload. In this book, readers will also find an overview of the X-ray structures of glucocorticoid receptor antagonists and a list of all the earlier reviews that cover part of the medicinal chemistry story of GRM collated by keywords organized in a table. With several examples of crystal structures and molecular modeling, this book illustrates the huge effort by multiple companies and research groups to develop glucocorticoid receptor modulators. Professionals and scholars alike will find it a handy tool, and appreciate the latest research findings that it presents.

Authors and Affiliations

  • AbbVie Bioresearch Center, Drug Discovery Science and Technology, Worcester, USA

    Adrian Hobson

About the author

Adrian Hobson, FRSC, is a Senior Research Fellow at Abbvie, and an adjunct Professor of Chemistry at Clark University in Worcester, MA, USA. With 30 years of experience as a medicinal chemist, he started his journey at Boots Pharmaceuticals, Nottingham UK, where he worked on anti-depressants and anti-psychotics, and in the Special Synthesis group making metabolites and possible impurities. After the company was acquired by BASF in 1994, he formed the High Speed Analoging team, working there for 6 years until he transferred to the BASF Bioresearch Corporation at Worcester, MA, USA, where he formed a new High Speed Analoging team to support both oncology and immunology. He spent the next 12 years working in medicinal chemistry on kinase, GPCR and NHR targets including selective glucocorticoid receptor modulators. When AbbVie split from Abbott, Dr Hobson switched his attention to immunology antibody-drug conjugates, where he has pioneered the use of glucocorticoid receptor modulators (GRM) as a payload for antibody-drug conjugates.


Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation